Yi Que

891 citations

51 papers · 595 indexed · h-index 14

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- CAR-T cell therapy research
Immunology
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in ⓘ

Oncology 31
- Cancer Immunotherapy and Biomarkers 10
- CAR-T cell therapy research 7
- Lung Cancer Research Studies 6
Neurology 18
- Neuroblastoma Research and Treatments 16

Co-authors: Xing Zhang (20 shared papers)Yao Liang (5 shared papers)Wei Xiao (5 shared papers)Yizhuo Zhang (22 shared papers)Yuanxiang Guan (5 shared papers)Wei Xiao (6 shared papers)Yongming Chen (2 shared papers)Zhiwei Zhou (2 shared papers)
Journals: Journal of Clinical Oncology (5 papers)BMC Cancer (4 papers)Frontiers in Immunology (3 papers)Cell Death and Disease (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)
Partner nations: China United States

In The Last Decade

Yi Que

47 papers receiving 588 citations

Peers

Countries citing papers authored by Yi Que

Since Specialization

Citations

This map shows the geographic impact of Yi Que's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Que with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Que more than expected).

Fields of papers citing papers by Yi Que

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Que. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Que. The network helps show where Yi Que may publish in the future.

Co-authors

The 25 scholars most cited alongside Yi Que, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yi Que Line = papers co-authored together Yi Que links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis Journal of Cancer ·Yi Que, Wei Xiao, Yuan-xiang Guan, Yao Liang, Shu-Mei Yan, Huo-ying Chen, Qiao-Qiao Li, Bu-shu Xu, Zhiwei Zhou, Xing Zhang	2017	82
2	Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma Journal for ImmunoTherapy of Cancer ·Yi Que, Xiao-Long Zhang, Zexian Liu, Jingjing Zhao, Qiuzhong Pan, Xizhi Wen, Wei Xiao, Bu-Shu Xu, Dong‐Chun Hong, Tianhui Guo, Lujun Shen, Weijun Fan, Huoying Chen, Desheng Weng, Hairong Xu, Penghui Zhou, Yizhuo Zhang, Xiaohui Niu, Xing Zhang	2021	67
3	Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma BMC Cancer ·Yi Que, Haibo Qiu, Yuanfang Li, Yongming Chen, Wei Xiao, Zhiwei Zhou, Xing Zhang	2015	56
4	LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival Cancer Biology and Medicine ·Yi Que, Fang Zhixin, Guan Yuanxiang, Wei Xiao, Xu Bushu, Jingjing Zhao, Chen Huoying, Xin‐Ke Zhang, Zeng Musheng, Yao Liang, Xing Zhang	2019	45
5	Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma BMC Cancer ·Yao Liang, Wei Wang, Yi Que, Yuanxiang Guan, Wei Xiao, Cheng Fang, Xing Zhang, Zhiwei Zhou	2018	35
6	Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis Cancer Management and Research ·Yi Que, Yao Liang, Jingjing Zhao, Ya Ding, Ruiqing Peng, Yuanxiang Guan, Xing Zhang	2018	26
7	ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma Cell Death and Disease ·Mengzhen Li, Chengtao Sun, Xiaoyun Bu, Yi Que, Lian Zhang, Yu Zhang, Li Zhang, Suying Lü, Junting Huang, Jia Zhu, Juan Wang, Feifei Sun, Yizhuo Zhang	2021	23
8	KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis Cell Death and Disease ·Binbin Chen, Huimou Chen, Suying Lü, Xiaoqin Zhu, Yi Que, Yu Zhang, Junting Huang, Li Zhang, Yu Zhang, Feifei Sun, Juan Wang, Jia Zhu, Zijun Zhen, Yizhuo Zhang	2022	22
9	Combined Use of the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as a Prognostic Predictor in Patients with Operable Soft Tissue Sarcoma Journal of Cancer ·Yao Liang, Wei Wang, Jingjing Li, Yuanxiang Guan, Yi Que, Wei Xiao, Xing Zhang, Zhiwei Zhou	2018	20
10	The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer Oncology Reports ·Feng Jiang, Bo‐Hua Kuang, Yi Que, Zhi-Rui Lin, Yuan Li, Wei Xiao, Ruiqing Peng, Xiaoshi Zhang, Xing Zhang	2015	18
11	Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma Cancer ·Wei Xiao, Jinghua Wang, Xizhi Wen, Bu-Shu Xu, Yi Que, Kuai Yu, Liping Xu, Jingjing Zhao, Qiuzhong Pan, Penghui Zhou, Xing Zhang	2020	16
12	ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma Oncogene ·Bu-shu Xu, Huo-ying Chen, Yi Que, Wei Xiao, Mu‐Sheng Zeng, Xing Zhang	2019	14
13	FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma Cancer Gene Therapy ·Wei Xiao, Liping Xu, Jinghua Wang, Kuai Yu, Bu-Shu Xu, Yi Que, Jingjing Zhao, Qiuzhong Pan, Chengqi Gao, Penghui Zhou, Xing Zhang	2024	14
14	Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8+ T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma Frontiers in Immunology ·Huoying Chen, Qianming Chen, Hongbo Liu, Yi Que, Xing Zhang, Fang Zheng	2018	13
15	Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov Journal for ImmunoTherapy of Cancer ·Yi Que, Yang Hu, Dong‐Chun Hong, Yizhuo Zhang	2021	11
16	Clinical Significance of Preoperative Serum High Density Lipoprotein Cholesterol Levels in Soft Tissue Sarcoma Medicine ·Yi Que, Feng Jiang, Liting Liu, Yuanfang Li, Yongming Chen, Haibo Qiu, Zhiwei Zhou, Xing Zhang	2015	11
17	A Pan-Cancer Analysis of IRAK1 Expression and Their Association With Immunotherapy Response Frontiers in Molecular Biosciences ·Mengmeng Liu, Yi Que, Ye Hong, Lian Zhang, Xing Zhang, Yizhuo Zhang	2022	10
18	Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma Clinical & Experimental Immunology ·Xiuxia Lu, Mengmeng Liu, Jing Yang, Yi Que, Xing Zhang	2022	9
19	A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure OncoTargets and Therapy ·Wei Xiao, Yi Que, Ruiqing Peng, Ya Ding, Jingjing Zhao, Xizhi Wen, Desheng Weng, Xiaoshi Zhang, Yuanxiang Guan, Xing Zhang	2018	9
20	Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer Frontiers in Immunology ·Yi Que, Juan Wang, Jia Zhu, Na Li, Junting Huang, Suying Lü, Feifei Sun, Lian Zhang, Zijun Zhen, Li Zhang, Ruiqing Cai, Haixia Guo, Xiaofei Sun, Yizhuo Zhang	2021	9

About Yi Que

Yi Que is a scholar working on Oncology, Neurology, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 51 papers that have together received 595 indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (16 papers), Sarcoma Diagnosis and Treatment (16 papers), Cancer Immunotherapy and Biomarkers (10 papers), Lymphoma Diagnosis and Treatment (7 papers), CAR-T cell therapy research (7 papers), Lung Cancer Research Studies (6 papers), Immune Cell Function and Interaction (4 papers) and Histone Deacetylase Inhibitors Research (4 papers). The work is most often cited by research in Oncology (347 citations), Immunology (139 citations), Pulmonary and Respiratory Medicine (208 citations), Cancer Research (84 citations) and Pathology and Forensic Medicine (57 citations). Yi Que has collaborated with scholars based in China and United States. Frequent co-authors include Xing Zhang, Yao Liang, Wei Xiao, Yizhuo Zhang, Yuanxiang Guan, Wei Xiao, Yongming Chen, Zhiwei Zhou, Yuanfang Li and Haibo Qiu. Their work appears in journals such as Journal of Clinical Oncology, BMC Cancer, Frontiers in Immunology, Cell Death and Disease and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact